ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
10.31
-0.19 (-1.81%)
At close: Jun 27, 2025, 4:00 PM
10.40
+0.09 (0.87%)
After-hours: Jun 27, 2025, 7:47 PM EDT
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 115 employees as of December 31, 2024. The number of employees increased by 15 or 15.00% compared to the previous year.
Employees
115
Change (1Y)
15
Growth (1Y)
15.00%
Revenue / Employee
n/a
Profits / Employee
-$1,155,278
Market Cap
878.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Dec 31, 2021 | 78 | 17 | 27.87% |
| Dec 31, 2020 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ORIC News
- 21 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
- 4 weeks ago - ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewsWire
- 4 weeks ago - ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - GlobeNewsWire
- 4 weeks ago - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC - GlobeNewsWire
- 7 weeks ago - ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - GlobeNewsWire
- 2 months ago - ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire